Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Edwards Lifesciences Reports Third Quarter Results

      Edwards Lifesciences logo. (PRNewsFoto/Edwards Lifesciences Corporation)

      News provided by

      Edwards Lifesciences Corporation

      Oct 23, 2018, 16:15 ET

      Share this article

      Share this article


      IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2018.

      Third Quarter and Recent Highlights:

      • Sales grew 10 percent; underlying1 sales grew 11 percent
      • Global THVT sales grew 16 percent; underlying sales increased 13 percent
      • EPS grew 34 percent; adjusted1 EPS grew 27 percent
      • Reconfirmed 2018 total company adjusted sales and EPS guidance ranges
      • Fourth quarter THVT underlying sales guidance moderated; Critical Care guidance raised
      • Commencement of U.S. study and European introduction of CENTERA valve system
      • Approval to begin US pivotal study of PASCAL mitral repair system

      "We are pleased to report strong third quarter performance that delivered 11 percent sales growth on an underlying basis, consistent with our expectations, driven by our impressive portfolio of innovative technologies.  Our results to-date keep us on track for another year of strong financial performance while we also aggressively invest in our future growth," said Michael A. Mussallem, chairman and CEO.  "Looking forward, based on recent learnings, we have increased confidence that our innovative lifesaving therapies can benefit many more patients whose structural heart disease is deadly and undertreated today."

      Third Quarter 2018 Results

      Sales for the quarter ended September 30, 2018 were $907 million, up 10 percent.  Total adjusted sales were $921 million, up 11 percent over the third quarter last year. Diluted earnings per share for the quarter was $1.06 per share, while adjusted earnings per share grew 27 percent to $1.07.

      Transcatheter Heart Valve Therapy (THVT)

      For the quarter, the company reported THVT sales of $558 million, a 16 percent growth rate over the third quarter last year, or 13 percent on an underlying basis.  Estimated global TAVR procedures continued to grow robustly in the mid-teens.  Edwards' worldwide sales grew at a lower rate due to a modest year-over-year share decline outside the U.S. and lower royalty revenues. Globally, the company's average selling price remained stable.

      Edwards is implementing a targeted commercial introduction in Europe of its feature-rich CENTERA platform and remains on track to receive a CE Mark of the SAPIEN 3 Ultra system in the fourth quarter.  The company has also decided to implement a controlled rollout strategy for the SAPIEN 3 Ultra system in Europe to ensure high procedural success of this advanced valve and delivery system.

      Transcatheter Mitral and Tricuspid Therapies

      In an important development at a recent medical meeting, favorable results from a large clinical trial clearly demonstrated the importance of reducing mitral regurgitation, reinforcing confidence in Edwards' strategy to address this large opportunity with its portfolio of therapies.  Third quarter sales of the Cardioband system, included in THVT, were limited due to the ongoing supply constraint that is expected to continue in the fourth quarter.   And, Edwards is pleased to announce the approval of its U.S. pivotal trial to study the PASCAL mitral repair system in patients with primary mitral regurgitation.

      Surgical Heart Valve Therapy and Critical Care

      Surgical Heart Valve Therapy sales for the quarter were $185 million, down 6 percent compared to the third quarter last year, or up 3 percent on an underlying basis.  Growth was driven by solid aortic unit volume and continued adoption of its new premium aortic valves.  Edwards also began launching its INSPIRIS RESILIA aortic valve in Japan last month.

      Critical Care sales were $164 million for the quarter, representing an increase of 14 percent versus last year, or 15 percent on an underlying basis.  This performance was strong across all product lines, led primarily by demand for HemoSphere.  Sales in the U.S. were particularly robust this quarter, additionally aided by new Group Purchasing Organization contracts, and 2018 underlying sales growth is now expected to exceed the top end of its full year guidance range of 6 to 8 percent.

      Additional Financial Results

      For the quarter, the company's adjusted gross profit margin was 75.5 percent, compared to 74.4 percent in the same period last year. This improvement primarily reflects the benefit of a more profitable product mix and the absence of last year's expenses associated with Hurricane Maria in Puerto Rico. These benefits were partially offset by continued investments in capacity.

      Selling, general and administrative expenses increased 10 percent to $270 million for the quarter, driven by personnel related expenses.

      Research and development investments for the third quarter increased 13 percent to $162 million, or 18 percent of sales. This increase was primarily the result of continued investments in transcatheter programs, including spending on clinical trials.

      The tax rate for the quarter was 9.2 percent, down from 19.7 percent in the prior year period.  This reduction was driven by U.S. tax reform.  Excluding the impact of special items, the tax rate would have been 14 percent.

      Free cash flow for the third quarter was $257 million, defined as cash flow from operating activities of $342 million, less capital spending of $85 million.

      Cash, cash equivalents and short-term investments totaled $1.6 billion at September 30, 2018.  Total debt was $1.2 billion.

      Outlook

      Overall, sales guidance for total Edwards remains unchanged at the higher end of its range of $3.5 to $3.9 billion.  Underlying sales growth in THVT for the first nine months was 12.5 percent and the company expects its full year 2018 growth to remain in that area because of a limited contribution from Cardioband and a revised rollout strategy for SAPIEN 3 Ultra.  Additionally, the company continues to expect full year 2018 adjusted earnings per share to be between $4.60 and $4.75.

      For the fourth quarter 2018, at current foreign exchange rates, the company projects adjusted sales to be between $950 million and $1 billion, and adjusted EPS of $1.05 to $1.20.

      "We remain confident in our outlook for continued strong sales growth, and are passionate about helping more patients around the world.  We continue to focus on driving organic growth with leading innovative technologies, while aggressively investing in our future.  Our foundation of leadership, coupled with a robust product pipeline, positions us well for continued longer-term success and greater shareholder value as we pursue multi-billion dollar market opportunities," said Mussallem.

      About Edwards Lifesciences        

      Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

      Conference Call and Webcast Information          

      Edwards Lifesciences will be hosting a conference call today at 2:00 p.m. PT to discuss its third quarter results.  To participate in the conference call, dial (877) 704-2848 or (201) 389-0893.  For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13683434.  The call will also be available via live or archived webcast on the "Investor Relations" section of the Edwards web site at ir.edwards.com or www.edwards.com. A live stream and archived replay can also be accessed via mobile devices by downloading Edwards' IR App for iPhone and iPad or Android.

      This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident"  or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Mussallem, full year and fourth quarter 2018 financial guidance, statements regarding the potential for future products, projected product approvals and commercial launch strategies, and information in the Outlook section.  Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.  The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.  If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

      Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.  Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with therapy adoption, particularly in THVT; unpredictability of the timing and impact of new product launches; competitive dynamics and changes in commercial strategies; the timing and extent of regulatory approvals and changes to reimbursement levels for the company's products; the company's success in developing new products and avoiding manufacturing and quality issues; the impact of currency exchange rates; the timing or results of R&D and clinical trials; unanticipated actions by the U.S. Food and Drug Administration and other regulatory agencies; unexpected litigation impacts or expenses; and other risks detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017. These filings, along with important safety information about our products, may be found at edwards.com.

      Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, Edwards CENTERA, CENTERA, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, HemoSphere, INSPIRIS RESILIA and PASCAL are trademarks of Edwards Lifesciences Corporation.  All other trademarks are the property of their respective owners.









      [1] 

      "Adjusted" amounts are non-GAAP items.  Adjusted sales, or "underlying"  or "organic" growth rates, in this press release exclude foreign exchange fluctuations and a sales return reserve related to a surgical heart valve consignment conversion. Adjusted sales and "underlying" or "organic" growth rates also exclude the prior year positive impact of THVT stocking sales in Germany, and the negative impact of de-stocking. Adjusted earnings per share is a non-GAAP item computed on a diluted basis and in this press release excludes intellectual property litigation expenses, amortization of intellectual property, fair value adjustments to contingent consideration liabilities arising from acquisitions, a sales return reserve related to a surgical heart valve consignment conversion, impairment of long-lived assets, realignment expenses, a pension curtailment gain, the impact of THVT stocking sales in Germany, and the impact from implementation of tax law changes and audit settlements. See the Non-GAAP Financial Information page and reconciliation tables below.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Consolidated Statements of Operations

      (in millions, except per share data)



      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,


      2018


      2017


      2018


      2017

      Net sales

      $

      906.6



      $

      821.5



      $

      2,745.1



      $

      2,546.8


      Cost of sales

      224.9



      213.3



      704.7



      640.0










      Gross profit

      681.7



      608.2



      2,040.4



      1,906.8










      Selling, general, and administrative expenses

      269.5



      244.6



      800.4



      718.0


      Research and development expenses

      161.8



      142.9



      459.1



      406.0


      Intellectual property litigation expenses

      7.9



      13.7



      19.1



      31.6


      Change in fair value of contingent consideration liabilities, net

      (6.4)



      (16.7)



      8.3



      (12.5)


      Special charges, net

      —



      9.7



      —



      9.7


      Other operating expenses, net

      —



      —



      —



      0.7










      Operating income

      248.9



      214.0



      753.5



      753.3










      Interest expense (income), net

      0.5



      0.1



      (0.3)



      3.9


      Special charges (gains), net

      —



      0.5



      (7.1)



      31.7


      Other (income) expense, net

      (0.3)



      1.6



      (2.3)



      6.7










      Income before provision for income taxes

      248.7



      211.8



      763.2



      711.0










      Provision for income taxes

      22.8



      41.7



      48.0



      124.6










      Net income

      $

      225.9



      $

      170.1



      $

      715.2



      $

      586.4










      Earnings per share:








      Basic

      $

      1.08



      $

      0.81



      $

      3.41



      $

      2.78


      Diluted

      $

      1.06



      $

      0.79



      $

      3.34



      $

      2.71










      Weighted-average common shares outstanding:








      Basic

      209.0



      211.3



      209.5



      211.0


      Diluted

      213.2



      216.2



      214.1



      216.1










      Operating statistics








      As a percentage of net sales:








      Gross profit

      75.2

      %


      74.0

      %


      74.3

      %


      74.9

      %

      Selling, general, and administrative expenses

      29.7

      %


      29.8

      %


      29.2

      %


      28.2

      %

      Research and development expenses

      17.8

      %


      17.4

      %


      16.7

      %


      15.9

      %

      Operating income

      27.5

      %


      26.0

      %


      27.4

      %


      29.6

      %

      Income before provision for income taxes

      27.4

      %


      25.8

      %


      27.8

      %


      27.9

      %

      Net income

      24.9

      %


      20.7

      %


      26.1

      %


      23.0

      %









      Effective tax rate

      9.2

      %


      19.7

      %


      6.3

      %


      17.5

      %




      Note: Numbers may not calculate due to rounding.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Balance Sheets

      (in millions)



      September 30, 2018


      December 31, 2017

      ASSETS








      Current assets




      Cash and cash equivalents

      $

      1,261.3



      $

      818.3


      Short-term investments

      334.4



      519.2


      Accounts and other receivables, net

      530.1



      479.3


      Inventories, net

      583.8



      554.9


      Prepaid expenses

      52.6



      60.6


      Other current assets

      150.4



      116.9


      Total current assets

      2,912.6



      2,549.2






      Long-term investments

      479.0



      567.0


      Property, plant, and equipment, net

      826.1



      679.7


      Goodwill

      1,122.3



      1,126.5


      Other intangible assets, net

      467.9



      468.0


      Deferred income taxes

      115.1



      167.1


      Other assets

      35.2



      108.9






      Total assets

      $

      5,958.2



      $

      5,666.4






      LIABILITIES AND STOCKHOLDERS' EQUITY








      Current liabilities




      Accounts payable and accrued liabilities

      $

      661.2



      $

      770.3


      Short-term debt

      599.9



      598.0


      Contingent consideration liabilities

      —



      51.7


      Total current liabilities

      1,261.1



      1,420.0






      Long-term debt

      593.6



      438.4


      Contingent consideration liabilities

      192.6



      192.6


      Taxes payable

      264.5



      347.5


      Uncertain tax positions

      125.3



      164.6


      Other long-term liabilities

      159.8



      147.1






      Stockholders' equity




      Common stock

      214.8



      212.0


      Additional paid-in capital

      1,341.2



      1,166.9


      Retained earnings

      2,687.7



      1,962.1


      Accumulated other comprehensive loss

      (139.0)



      (132.7)


      Treasury stock, at cost

      (743.4)



      (252.1)


      Total stockholders' equity

      3,361.3



      2,956.2






      Total liabilities and stockholders' equity

      $

      5,958.2



      $

      5,666.4


      EDWARDS LIFESCIENCES CORPORATION
      Non-GAAP Financial Information

      To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP historical financial measures.  Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations).  The Company uses the term "adjusted sales" or "underlying growth rate" when referring to non-GAAP sales information, which excludes foreign exchange fluctuations, the conversion to a consignment inventory system for surgical heart valves ("SHV"), and the positive impact of transcatheter heart valve therapy ("THVT") stocking sales in Germany and the negative impact of de-stocking. The Company uses the term "adjusted" to also exclude intellectual property litigation income and expenses, amortization of intellectual property, fair value adjustments to contingent consideration liabilities arising from acquisitions, gains and losses from significant investments, impairments, litigation, the positive impact of THVT stocking sales in Germany and the negative impact of de-stocking, realignment expenses, the conversion to a consignment inventory system for SHV, charitable contributions to the Edwards Lifesciences Foundation, significant business development transactions, significant pension curtailment or settlement gains and losses, and the impact from implementation of tax law changes.

      Fluctuations in exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Reconciliation of Sales by Product Group and Region."

      Guidance for sales and sales growth rates is provided on an "underlying basis," and projections for diluted earnings per share, net income and growth, gross profit margin, taxes, and free cash flow are also provided on a non-GAAP basis as adjusted for the items identified above due to the inherent difficulty in forecasting such items.  The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.

      Management considers free cash flow to be a liquidity measure which provides useful information to management and investors about the amount of cash generated by business operations, after deducting payments for capital expenditures, which can then be used for strategic opportunities or other business purposes including, among others, investing in the Company's business, making strategic acquisitions, strengthening the balance sheet, and repurchasing stock.

      Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance.  These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods.

      Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.  A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below.

      The items described below are adjustments to the GAAP financial results in the reconciliations that follow:

      SHV Consignment Conversion - In the first, second, and third quarters of 2018, the Company recorded a sales return reserve of $34.7 million ($30.8 million, net of related costs), $28.4 million ($24.6 million, net of related costs) and $14.4 million ($12.9 million, net of related costs), respectively, related to its conversion to a consignment inventory system for surgical heart valves.

      THVT Germany Stocking Sales - In the first quarter of 2017, the Company recorded $61.8 million in net stocking sales ($48.0 million, net of related costs) to customers in Germany, as these customers elected to purchase additional inventory in anticipation of a potential supply interruption resulting from intellectual property litigation.  In the second and third quarters of 2017, these customers consumed on a net basis $22.5 million ($17.9 million, net of related costs) and $17.0 million ($13.3 million, net of related costs), respectively, of their stocking inventory.  In the first quarter of 2018, these customers consumed on a net basis $8.0 million ($6.0 million, net of related costs) of their stocking inventory.

      Intellectual Property Litigation Expenses - The Company incurred intellectual property litigation expenses of $5.7 million and $10.2 million in the first quarter of 2018 and 2017, respectively, $5.5 million and $7.7 million in the second quarter of 2018 and 2017, respectively, and $7.9 million and $13.7 million in the third quarter of 2018 and 2017, respectively.

      Change in Fair Value of Contingent Consideration Liabilities, net - The Company recorded expenses related to changes in the fair value of its contingent consideration liabilities arising from acquisitions in the amount of $3.8 million and $1.1 million in the first quarter of 2018 and 2017, respectively, and $10.9 million and $3.1 million in the second quarter of 2018 and 2017, respectively, and gains of $6.4 million and $16.7 million in the third quarter of 2018 and 2017, respectively.

      Amortization of Intellectual Property - The Company recorded amortization expense related to intellectual property in the amount of $0.6 million and $2.1 million in the first quarter of 2018 and 2017, respectively, $0.7 million and $2.0 million in the second quarter of 2018 and 2017, respectively, and $0.6 million and $2.1 million in the third quarter of 2018 and 2017, respectively.

      Impairment of Long-lived Assets - The Company recorded a $31.2 million charge in the second quarter of 2017 related to the other-than-temporary impairment of one of its cost method investments and an associated long-term asset related to the Company's option to acquire this investee.

      Realignment Expenses - The Company recorded a $10.2 million charge in the third quarter of 2017 related to the severance expenses and other costs associated with the closure of its manufacturing plant in Switzerland.

      Pension Curtailment Gain - The Company recorded a $7.1 million gain in the first quarter of 2018 related to the curtailment of its defined benefit plan resulting from the closure of its manufacturing plant in Switzerland.

      Provision for Income Taxes - During the first quarter of 2018, the Company recorded a $24.0 million tax expense to adjust its estimated provisional amounts related to the implementation of U.S. tax law changes. During the second quarter of 2018, the Company recorded a $36.1 million tax benefit related to the settlement of tax audits and a $17.3 million benefit related to the reorganization of a foreign entity and adjustments to estimated provisional amounts resulting from the U.S. tax law changes. During the third quarter of 2018, the Company recorded an additional $4.6 million benefit related to the reorganization of a foreign entity. The income tax impact of the expenses and gains discussed above is based upon the items' forecasted effect upon the Company's full year effective tax rate.  Adjustments to forecasted items unrelated to these expenses and gains, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods.

      Adjusted Free Cash Flow - The Company defines free cash flow as cash flows from operating activities less capital expenditures.  During 2018, the Company also excluded from its calculation of free cash flow payments related to tax audit settlements and the repatriation tax resulting from the U.S. tax law changes.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Reconciliation of GAAP to Non-GAAP Financial Information

      (in millions, except per share and percentage data)


      RECONCILIATION OF GAAP TO ADJUSTED OPERATING INCOME




      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,



      2018


      2017


      2018


      2017

      GAAP Operating Income


      $

      248.9



      $

      214.0



      $

      753.5



      $

      753.3


      Growth Rate %


      16.3

      %




      —

      %












      Non-GAAP adjustments: (A)









      SHV consignment conversion


      12.9



      —



      68.3



      —


      THVT Germany stocking sales


      —



      13.3



      6.0



      (16.8)


      Intellectual property litigation expenses


      7.9



      13.7



      19.1



      31.6


      Change in fair value of contingent consideration liabilities, net


      (6.4)



      (16.7)



      8.3



      (12.5)


      Amortization of intellectual property


      0.6



      2.1



      1.9



      6.2


      Realignment expenses


      —



      9.7



      —



      9.7


      Adjusted Operating Income


      $

      263.9



      $

      236.1



      $

      857.1



      $

      771.5


      Growth Rate %


      11.8

      %




      11.1

      %





      RECONCILIATION OF GAAP TO ADJUSTED NET INCOME




      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,



      2018


      2017


      2018


      2017

      GAAP Net Income


      $

      225.9



      $

      170.1



      $

      715.2



      $

      586.4


      Growth Rate %


      32.8

      %




      22.0

      %












      Non-GAAP adjustments: (A)









      SHV consignment conversion


      12.9



      —



      68.3



      —


      THVT Germany stocking sales


      —



      13.3



      6.0



      (16.8)


      Intellectual property litigation expenses


      7.9



      13.7



      19.1



      31.6


      Change in fair value of contingent consideration liabilities, net


      (6.4)



      (16.7)



      8.3



      (12.5)


      Amortization of intellectual property


      0.6



      2.1



      1.9



      6.2


      Impairment of long-lived assets


      —



      —



      —



      31.2


      Realignment expenses


      —



      10.2



      —



      10.2


      Pension curtailment gain


      —



      —



      (7.1)



      —











      Provision for income taxes









      Tax effect on reconciling items (B)


      (8.3)



      (9.2)



      (22.2)



      (18.0)


      Tax audit settlements


      —



      —



      (36.1)



      —


      Impacts from U.S. tax legislation


      (4.6)



      —



      2.1



      —


      Ongoing tax impact of non-fourth quarter items (D)


      0.1



      (1.7)



      0.2



      (1.7)


      Adjusted Net Income


      $

      228.1



      $

      181.8



      $

      755.7



      $

      616.6


      Growth Rate %


      25.5

      %




      22.6

      %





      RECONCILIATION OF GAAP TO ADJUSTED DILUTED EARNINGS PER SHARE




      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,



      2018


      2017


      2018


      2017

      GAAP Diluted Earnings Per Share


      $

      1.06



      $

      0.79



      $

      3.34



      $

      2.71


      Growth Rate %


      34.2

      %




      23.2

      %












      Non-GAAP adjustments: (A), (C)









      SHV consignment conversion


      0.04



      —



      0.25



      —


      THVT Germany stocking sales


      —



      0.05



      0.02



      (0.06)


      Intellectual property litigation expenses


      0.03



      0.04



      0.07



      0.10


      Change in fair value of contingent consideration liabilities, net


      (0.04)



      (0.08)



      0.03



      (0.05)


      Amortization of intellectual property


      —



      0.01



      0.01



      0.02


      Impairment of long-lived assets


      —



      —



      —



      0.10


      Realignment expenses


      —



      0.04



      —



      0.04


      Pension curtailment gain


      —



      —



      (0.03)



      —











      Provision for income taxes









      Tax audit settlements


      —



      —



      (0.17)



      —


      Impacts from U.S. tax legislation


      (0.02)



      —



      0.01



      —


      Ongoing tax impact of non-fourth quarter items (D)


      —



      (0.01)



      —



      (0.01)


      Adjusted Diluted Earnings Per Share


      $

      1.07



      $

      0.84



      $

      3.53



      $

      2.85


      Growth Rate %


      27.4

      %




      23.9

      %














      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.



      (B)

      The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable.  The tax effect on the THVT Germany stocking sales adjustment is calculated using the global effective tax rate.



      (C) 

      All amounts are tax effected, calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable.



      (D)

      Quarterly adjustment required to spread the full year tax impact of previously reported items.

      RECONCILIATION OF GAAP TO ADJUSTED GROSS PROFIT MARGIN




      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,



      2018


      2017


      2018


      2017

      GAAP Gross Profit Margin


      75.2

      %


      74.0

      %


      74.3

      %


      74.9

      %










      Non-GAAP adjustments: (A)









      SHV consignment conversion


      0.2



      —



      0.4



      —


      THVT Germany stocking sales


      —



      0.1



      —



      —


      Amortization of intellectual property


      0.1



      0.3



      0.1



      0.2


      Adjusted Gross Profit Margin


      75.5

      %


      74.4

      %


      74.8

      %


      75.1

      %








      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.

      RECONCILIATION OF GAAP TO NON-GAAP TAX RATE




      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,



      2018


      2017


      2018


      2017

      GAAP Tax Rate


      9.2

      %


      19.7

      %


      6.3

      %


      17.5

      %










      Non-GAAP adjustments: (A)









      Tax audit settlements


      —



      —



      4.3



      —


      Impacts from U.S. tax legislation


      1.8



      —



      (0.3)



      —


      SHV consignment conversion


      1.2



      —



      1.1



      —


      THVT Germany stocking sales


      —



      0.1



      0.1



      (0.1)


      Intellectual property litigation expenses


      0.5



      1.1



      0.4



      0.7


      Change in fair value of contingent consideration liabilities, net


      0.8



      1.1



      0.2



      0.2


      Amortization of intellectual property


      —



      0.1



      —



      0.1


      Impairment of long-lived assets


      —



      0.7



      —



      0.7


      Realignment expenses


      —



      (0.4)



      —



      (0.1)


      Non-GAAP Tax Rate


      13.5

      %


      22.4

      %


      12.1

      %


      19.0

      %








      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.

      RECONCILIATION OF GAAP OPERATING CASH FLOW TO ADJUSTED FREE CASH FLOW



      Nine Months
      Ended
      September 30,
      2018

      Net cash provided by operating activities

      $

      633.8

      Capital expenditures

      (181.1)

      Tax audit settlements

      56.7

      Repatriation tax payments

      41.0

      Adjusted Free Cash Flow (A)

      $

      550.4








      (A) 

      See description of "Adjusted Free Cash Flow" on the Non-GAAP Financial Information page.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Reconciliation of GAAP to Non-GAAP Financial Information

      ($ in millions)


      RECONCILIATION OF SALES BY PRODUCT GROUP AND REGION












      2018 Adjusted


      2017 Adjusted



      Sales by Product Group (QTD)


      3Q 2018


      3Q 2017


      Change


      GAAP

      Growth

       Rate*


      SHV Consignment Conversion

      Germany Stocking


      3Q 2018 Adjusted Sales


      Germany Stocking


      FX

       Impact


      3Q 2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      Transcatheter Heart Valve Therapy


      $

      557.8



      $

      481.2



      $

      76.6



      15.9

      %


      $

      —


      $

      —



      $

      557.8



      $

      17.0



      $

      (3.3)



      $

      494.9



      12.7

      %

      Surgical Heart Valve Therapy


      184.6



      195.6



      (11.0)



      (5.6)

      %


      14.4


      —



      199.0



      —



      (2.1)



      193.5



      2.8

      %

      Critical Care


      164.2



      144.7



      19.5



      13.5

      %


      —


      —



      164.2



      —



      (1.6)



      143.1



      14.7

      %

      Total


      $

      906.6



      $

      821.5



      $

      85.1



      10.4

      %


      $

      14.4


      $

      —



      $

      921.0



      $

      17.0



      $

      (7.0)



      $

      831.5



      10.8

      %


























      2018 Adjusted


      2017 Adjusted



      Sales by Product Group (YTD)


      YTD  3Q 2018


      YTD  3Q 2017


      Change


      GAAP

      Growth

       Rate*


      SHV Consignment Conversion

      Germany Stocking


      YTD 3Q 2018 Adjusted Sales


      Germany Stocking


      FX

      Impact


      YTD 3Q
      2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      Transcatheter Heart Valve Therapy


      $

      1,694.3



      $

      1,507.9



      $

      186.4



      12.4

      %


      $

      —


      $

      8.0



      $

      1,702.3



      $

      (22.3)



      $

      27.6



      $

      1,513.2



      12.5

      %

      Surgical Heart Valve Therapy


      554.4



      602.2



      (47.8)



      (7.9)

      %


      77.5


      —



      631.9



      —



      13.1



      615.3



      2.7

      %

      Critical Care


      496.4



      436.7



      59.7



      13.7

      %


      —


      —



      496.4



      —



      8.0



      444.7



      11.6

      %

      Total


      $

      2,745.1



      $

      2,546.8



      $

      198.3



      7.8

      %


      $

      77.5


      $

      8.0



      $

      2,830.6



      $

      (22.3)



      $

      48.7



      $

      2,573.2



      10.0

      %

































      2018 Adjusted


      2017 Adjusted



      Sales by Region (QTD)


      3Q 2018


      3Q 2017


      Change


      GAAP

      Growth
      Rate*


      SHV Consignment Conversion

      Germany Stocking


      3Q 2018 Adjusted Sales


      Germany Stocking


      FX

      Impact


      3Q 2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      United States


      $

      518.7



      $

      470.4



      $

      48.3



      10.2

      %


      $

      14.4


      $

      —



      $

      533.1



      $

      —



      $

      —



      $

      470.4



      13.3

      %

      Europe


      201.3



      182.3



      19.0



      10.5

      %


      —


      —



      201.3



      17.0



      (2.9)



      196.4



      2.5

      %

      Japan


      94.2



      83.2



      11.0



      13.3

      %


      —


      —



      94.2



      —



      (0.5)



      82.7



      13.9

      %

      Rest of World


      92.4



      85.6



      6.8



      8.0

      %


      —


      —



      92.4



      —



      (3.6)



      82.0



      12.7

      %

      International


      387.9



      351.1



      36.8



      10.5

      %


      —


      —



      387.9



      17.0



      (7.0)



      361.1



      7.4

      %

      Total


      $

      906.6



      $

      821.5



      $

      85.1



      10.4

      %


      $

      14.4


      $

      —



      $

      921.0



      $

      17.0



      $

      (7.0)



      $

      831.5



      10.8

      %


























      2018 Adjusted


      2017 Adjusted



      Sales by Region (YTD)


      YTD  3Q 2018


      YTD  3Q 2017


      Change


      GAAP

      Growth
      Rate*


      SHV Consignment Conversion

      Germany Stocking


      YTD 3Q 2018 Adjusted Sales


      Germany Stocking


      FX

      Impact


      YTD 3Q
      2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      United States


      $

      1,510.3



      $

      1,413.9



      $

      96.4



      6.8

      %


      $

      77.5


      $

      —



      $

      1,587.8



      $

      —



      $

      —



      $

      1,413.9



      12.3

      %

      Europe


      659.3



      627.0



      32.3



      5.2

      %


      —


      8.0



      667.3



      (22.3)



      41.6



      646.3



      3.2

      %

      Japan


      289.5



      253.0



      36.5



      14.5

      %


      —


      —



      289.5



      —



      4.9



      257.9



      12.3

      %

      Rest of World


      286.0



      252.9



      33.1



      13.1

      %


      —


      —



      286.0



      —



      2.2



      255.1



      12.1

      %

      International


      1,234.8



      1,132.9



      101.9



      9.0

      %


      —


      8.0



      1,242.8



      (22.3)



      48.7



      1,159.3



      7.2

      %

      Total


      $

      2,745.1



      $

      2,546.8



      $

      198.3



      7.8

      %


      $

      77.5


      $

      8.0



      $

      2,830.6



      $

      (22.3)



      $

      48.7



      $

      2,573.2



      10.0

      %


























      * Numbers may not calculate due to rounding.

      SOURCE Edwards Lifesciences Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.